Skip to content
10-Q

Quarterly Report

Contineum Therapeutics, Inc. CTNM

0001628280-26-030614

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 37.34M sh
Shares Diluted Q1 2026 · Mar 31, 2025 25.87M sh
Capex Q1 2026 · Mar 31, 2026 $312K
Capex Q1 2026 · Mar 31, 2025 $47K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$16.27M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.41M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $20.16M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $75.6M
Stockholders Equity Q1 2026 · Mar 31, 2026 $250.04M
Stockholders Equity Q1 2026 · Dec 31, 2025 $260.99M
Stockholders Equity Q1 2026 · Mar 31, 2025 $184.77M
Stockholders Equity Q1 2026 · Dec 31, 2024 $198.07M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.66M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.74M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $15.65M
Current Assets Q1 2026 · Mar 31, 2026 $252.96M
Current Assets Q1 2026 · Dec 31, 2025 $267.92M
Total Assets Q1 2026 · Mar 31, 2026 $261.35M
Total Assets Q1 2026 · Dec 31, 2025 $276.64M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.39
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.62
Eps Basic Q1 2026 · Mar 31, 2026 −$0.39
Eps Basic Q1 2026 · Mar 31, 2025 −$0.62
Sga Expense Q1 2026 · Mar 31, 2026 $5.26M
Sga Expense Q1 2026 · Mar 31, 2025 $4.4M
Rd Expense Q1 2026 · Mar 31, 2026 $11.65M
Rd Expense Q1 2026 · Mar 31, 2025 $13.71M
Net Income Q1 2026 · Mar 31, 2026 −$14.46M
Net Income Q1 2026 · Mar 31, 2025 −$15.99M
Operating Income Q1 2026 · Mar 31, 2026 −$16.9M
Operating Income Q1 2026 · Mar 31, 2025 −$18.11M